Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,208 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Powder Clear all

Conditions: Athletic Performance, Recovery, Sleep
Interventions: Magnesium glycinate, Magnesium L-threonate, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Enlarged Pores, Sebum Production
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee

Conditions: Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
Interventions: Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 29
States / cities: Birmingham, Alabama • Gadsden, Alabama • Mission Hills, California + 26 more

Conditions: Macular Telangiectasia Type 2 (MacTel)
Interventions: L-serine, Placebo; Drug · Other
Lead sponsor: The Lowy Medical Research Institute Limited; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: La Jolla, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more

Conditions: Oral Mucositis
Interventions: AG013, Placebo; Biological · Other
Lead sponsor: Oragenics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more

Conditions: Heart Defects, Congenital
Interventions: Clopidogrel (SR25990), placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Up to 92 Days
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Common Cold
Interventions: Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Allergic Bronchopulmonary Aspergillosis
Interventions: PUR1900, Placebo; Combination Product
Lead sponsor: Pulmatrix Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Denver, Colorado • New Haven, Connecticut • Hialeah, Florida + 6 more

Conditions: Cerebral Palsy, Spasticity
Interventions: IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight); Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more

Conditions: Asthma
Interventions: Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder, Placebo (1), Placebo (2); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 25
States / cities: Huntington Beach, California • Los Angeles, California • Riverside, California + 21 more

Conditions: Colorectal Neoplasm
Interventions: DS-8201a; Drug
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 6 more

Conditions: Mental Processes, Cognitive Change, Mood Change
Interventions: Placebo, Enovita Grape Seed Extract, Mirtoselect Bilberry Extract, Virtiva Plus Ginko Biloba Extract; Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cystic Fibrosis
Interventions: Ataluren (PTC124®), Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 6 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 30
States / cities: Birmingham, Alabama • Mobile, Alabama • Long Beach, California + 23 more

Conditions: Healthy Volunteers
Interventions: Technosphere® Insulin Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Height, Cognitive Function, Weight Gain
Interventions: NuBest Tall Growth Protein Powder, Placebo Powder; Dietary Supplement
Lead sponsor: NuBest; Industry
Eligibility: 10 Years to 16 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Rett Syndrome
Interventions: NNZ-2566, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 5 Years to 15 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Birmingham, Alabama • Oakland, California • San Diego, California + 9 more

Conditions: Glycogen Storage Disease Type II
Interventions: avalglucosidase alfa; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 0 Days to 12 Months
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Stanford, California • Minneapolis, Minnesota • Hawthorne, New York + 3 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Peoria, Illinois • Indianapolis, Indiana • Worcester, Massachusetts + 4 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 51
States / cities: Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more

Conditions: Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
Interventions: Promacta, blood drawing in patients with WAS, blood drawing in healthy controls; Drug · Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 3 Months to 80 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo, Questionnaire; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Jasper, Alabama • Clearwater, Florida • Orlando, Florida + 13 more

Conditions: Spinal Muscular Atrophy
Interventions: Sodium phenylbutyrate; Drug
Lead sponsor: University of Utah; Other
Eligibility: 1 Day to 6 Months
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Arterial Hypertension
Interventions: AV-101, Placebo; Drug
Lead sponsor: Aerovate Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more

Conditions: Metastatic Prostate Cancer
Interventions: Indoximod, Sipuleucel-T, Placebo; Biological · Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Male only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 4
States / cities: Chicago, Illinois • Minneapolis, Minnesota • New York, New York + 1 more

Search by objective public record fields.

UCLA Magnesium Formulation Athlete Study

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

Study of Serine Supplementation to Protect Vision in MacTel

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

Pharmacokinetic Study in Healthy Volunteers

A Study to Evaluate the Effects of a Dietary Supplement on Children's Health and Development Outcomes.

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa

Study of Ataluren (PTC124) in Hemophilia A and B

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects

Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer